StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy
Phase 3positiveRasonquePositive
AI Analysis
Summary
Revolution's Phase 3 RASolute 302 trial of daraxonrasib (Rasonque) in previously treated metastatic pancreatic ductal adenocarcinoma met its primary endpoint, demonstrating nearly double the median overall survival compared to standard chemotherapy. The company received historic FDA approval for the oral therapy, though shares remained flat despite the significant clinical achievement.
Clinical Trial Data
Outcome Details
Daraxonrasib demonstrated median overall survival of 13.2 months versus 6.7 months for standard-of-care chemotherapy in RASolute 302 trial
Importance:8/10
Sentiment:
0.85
pancreatic canceroral therapyPhase 3 dataFDA approvalRASolute 302
Read the original article
Published by GEN - Genetic Engineering & Biotech News on August 30, 2026 6:25 PM